News Hub | News Direct

NAVEX Opens Nominations for 2023 Customer Excellence Awards

NAVEX Global

NAVEX, the leader in integrated risk and compliance management software, today announced nominations are now open for the third annual NAVEX Customer Excellence Awards. This prestigious award acknowledges and celebrates the exceptional performance of NAVEX customers’ ethics, compliance and integrated risk management programs. The nomination window will be open until July 12, 2023. Previous Customer Excellence Award winners include Dell Technologies, Castolin Eutectic Holding GmbH, Jacksonville Transportation Authority and Genpact. Interested NAVEX customers can submit their entry today via the NAVEX Customer Excellence Award website. “A robust risk and compliance program is fundamental to creating and maintaining a highly motivated workplace culture,” said Steve Chapman, Chief Customer Officer at NAVEX. “Our annual excellence awards recognize especially strong programs that demonstrate measurable impact on business success. We look forward to seeing all of this year’s nominations.” The Customer Excellence Awards recognize exceptional program performances from NAVEX's 13,000+ customers worldwide, covering 70 million employees, categorized by company size and across three categories. Ethics & Compliance – Recognizes the exceptional ability to identify and mitigate risks, provide meaningful insights into corporate culture and drive risk aware decision-making through E&C programs. Integrated Risk Management – Recognizes the exceptional ability to adapt to specific risk landscapes, bring visibility to risk across the organization and use informed data to influence decisions that ultimately make for a more resilient and successful business. GRC Program of the Year – Recognizes the exceptional ability to break down silos across the business to align ethics and compliance, and/or integrated risk management, resulting in a comprehensive risk and compliance management program that provides efficiency and actionable insights. As in years past, an expert panel of judges will determine the winners, consisting of some of the most respected names in the industry, including Vera Cherepanova, Studio Etica; Matt Kelly, Radical Compliance; Michael Volkov, The Volkov Law Group; Kyle Welch, George Washington School of Business; Carol Williams, Strategic Decision Solutions; along with NAVEX executives Florian Haarhaus, International General Manager; Steve Chapman, Chief Customer Officer; and Carrie Penman, Chief Risk & Compliance Officer. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Scott Levesque +1 617-388-5773 scott.levesque@navex.com Company Website https://www.navex.com

May 03, 2023 08:30 AM Eastern Daylight Time

News Release

Matinas BioPharma shares lipid nanocrystal platform delivery for emerging anti-fungal drug

Matinas BioPharma

Matinas BioPharma CEO & Co-founder Jerry Jabbour joins Natalie Stoberman from the Proactive newsroom to discuss the company's latest growth and momentum surrounding its MAT2203 trial as a potential oral broad-spectrum treatment for invasive deadly fungal infections. Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company is also developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop novel formulations that capitalize on the unique characteristics of the LNC platform. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

May 02, 2023 02:16 PM Eastern Daylight Time

Video

Former L'Oréal President Jim Morrison, Chief Executive Officer of Emergent Health Corp. Reports Year to Year Revenue Increase of Over 380% and Quarter to Quarter Revenue Increase of Over 100%

Emergent Health Corp.

Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced today announced revenues of $373,406 for the quarter ended December 31, 2022 as compared to $185,471 for the quarter ended September 30, 2022, an increase of over 100% and revenues of $574,613 for the Year Ended December 31, 2022 as compared to $119,567 for the year ended December 31, 2021, an increase of over 380%. The financial statement can be viewed in its entirety at: https://www.otcmarkets.com/otcapi/company/financial-report/367945/content. Jim Morrison, former L'Oréal President and Emigrant’s new full time CEO stated, “The company is now engaged with several large biologics companies, and we expect enormous growth over the second and third quarter.” Emergent projects to continue increasing its revenues quarter to quarter as it expands its business internally and externally by acquisition. Recent Developments: On February 23, 2023, announced that it anticipates closing the acquisition to acquire Nanosthetic Cosmetic Labs (“Nanosthetic”) shortly. Nanosthetic, of Fort Lauderdale Florida, holds proprietary intellectual property that has been developed over the past ten years. The press release can be viewed in its entirety here. On February 21, 2023, Emergent on behalf of its subsidiary, Evolutionary Biologics, Inc., announced that it has executed a Letter of Intent to acquire a privately held company in the regenerative medical field. The company is profitable and does $5.4 Million in current revenues and projects a total of $9 Million in revenues for 2023. The press release can be viewed in its entirety here. The global biologics market size was valued at US $366.43 billion in 2021 and it is expected to hit over US$ 719.84 billion by 2030 with a noteworthy CAGR of 7.8% from 2022 to 2030. A biologic medication is a product that is made from live organisms and contains living organism components. Examples of biologics are Recombinant protein, tissues, allergens, genes, cells, blood components, blood, and vaccinations are all examples of biologics. Examples of what can be treated are Anemia, hemophilia, chronic migraine, hepatitis B, rheumatoid arthritis, inflammatory bowel disease, and other disorders and infections are treated with biologics. Our focus is on aesthetics cosmetics and men’s and women’s health, but also wound care and tissue regeneration. Various government efforts, higher share of biologics in the market, and rising use of biopharmaceuticals over chemically produced molecules, and many other factors are driving the biologics market expansion in the forecast period. ABOUT EMERGENT HEALTH CORPORATION Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses; Regen BioWellness, is a distributor of various products in the plant-based and regenerative medical fields. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter. Before using any products, you should always consult with your Veterinarian and/or Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: Jim Morrison, CEO Emergent Health Corporation Website i nfo@emergenthealthcompany.com Contact Details Emergent Health Corp. info@emergenthealthcompany.com Company Website https://emergenthealthcompany.com/

May 02, 2023 09:00 AM Eastern Daylight Time

Genflow Biosciences now "actively increasing" its presence in the US

Genflow Biosciences PLC

Genflow Biosciences PLC (LSE:GENF) CEO Dr Eric Leire spoke to Proactive after releasing final results for calendar year 2022 that show that the UK-based biotechnology company is fully funded for at least the next two years, despite its strong emphasis on R&D. Leire says that Genflow is "very excited" about the steps its taking to "actively increase" its presence in the US, where it has applied to trade its shares on the OTCQB Venture Market. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 02, 2023 07:45 AM Eastern Daylight Time

Video

Destiny Pharma's nasal spray project already delivering "more than hoped for"

Destiny Pharma PLC

Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Proactive after releasing fresh data from the update from a research collaboration into a novel biotherapeutic treatment for COVID-19 and influenza. Clark says that the project has already delivered "more than hoped for" and that it will be "really interesting to see where [it] goes next." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 02, 2023 07:30 AM Eastern Daylight Time

Video

Graft Polymer records "year of growth" against "somewhat challenging" backdrop

Graft Polymer (UK) PLC

Graft Polymer (UK) PLC (LSE:GPL) independent non-executive director Alex Brooks speaks to Thomas Warner from Proactive following the release of final results for calendar year 2022 - a year he describes as a "year of growth" despite it being a "somewhat challenging year" for its core customer base. Brooks goes on to talk about what's been achieved so far in 2023, adding that he "remains optimistic that market conditions are getting better" and expects another year of strong revenue growth. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 02, 2023 06:23 AM Eastern Daylight Time

Video

News Release

Ondine Biomedical shares potential impact of photodisinfection study on public health and safety

Ondine Biomedical Inc

Ondine Biomedical President and CTO Nicolas Loebel joins Natalie Stoberman from the Proactive studios to share how the latest results from its photodisinfection concept study can impact food safety in Canada and beyond. Loebel says the results of this study produced up to a 99.999% elimination of pathogens commonly found on hard surfaces in meat processing facilities, as well as those directly located on fresh-cut chicken, beef, and pork meat. Loebel adds these results could have direct impacts on community well-being and industry profitability by increasing consumer confidence in addition to reducing the strain on public health from food-borne illnesses. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

May 01, 2023 09:08 AM Eastern Daylight Time

Video

FS is on a Mission to Unleash Human Creativity. With a Relaunch of its Trend Forecasting Platform, the Future’s Looking Brighter for all Creators

Fashion Snoops

Earlier forecast timelines, dedicated specialty areas, advanced color inspiration, smoothly integrated with AI-powered market tracking and design tools — empowers creators to map their path ahead with extraordinary clarity. FS (Fashion Snoops) announces the relaunch of its popular future forecasting platform. The new rendition streamlines the product creation process; makes it more intuitive, interactive, and creatively fulfilling. Putting power into the hands of the creators, the FS platform provides advanced inspiration aimed to spark future ideas and help track what's happening in the market. Its range of custom tools enable subscribers to gather creative intelligence across retail, runways, trade shows, and social media. Most importantly, they help curate those discoveries into cutting-edge creative strategies and concepts. All in a format that is easy to customize, share, or export into design software. "The problem for creators today is not a lack of information, but rather an overload of it. That's where we come in, ” explains Itay Arad, Co-founder and CEO at FS. "Instead of just offering more, we present our clients with incisive, inspiring content that is easy to find and ready to provoke action." As a company with a purpose to unleash human creativity, the FS forecasting platform offers creatives a way to find joy and inspiration in the product development process. Once again. Feeding their imagination and passion for creating products that aren't driven solely by data or recent fads but by genuine innovation. "We realized that the market is desperately looking for a way to rekindle inspiration,” says Lilly Berelovich, Co-founder and Chief Creator at FS. “We are seeing too many brands and retailers trading in curiosity for a false sense of certainty. Relying so heavily on data and past successes that creativity and innovation are quickly diminishing. It's a catch-22 situation.” Berelovich continues, “Everyone is trying to figure out what consumers want, while the consumers are simply looking to be surprised and excited by newness from the brands... from our commitment to unleashing human creativity, we aim to help the market break this exhausting cycle.” Here are the highlights of features and tools on the renewed FS futures platform: TRACK AREA: FS subscribers can keep their finger on the pulse of what's happening across retail, social media, runways, and trade shows. FS's unique sorting and filtering algorithms make identifying trends and discovering inspiration for their future assortments fun and easy. EXPANDED CATEGORIES: Due to popular demand, the FS team has invested in and grown the offering for Activewear, Swimwear, and Intimates. Creators in these areas now have a section that speaks their language and focuses on their unique needs. COLOR TOOLS: FS's powerful suite of color tools includes a dynamic palette builder, an AI-enhanced runway color tracker, and the ability to search the platform's images by color. Aided by these tools and FS's in-depth color reports, subscribers can create their own original color palettes or use the ones built by FS as a starting point. Individual color chips and entire palettes can now be easily exported and uploaded to design software like Adobe Photoshop and InDesign. PATTERN + GRAPHICS AREA: Inspiration across markets or an individual design category can be found while accessing FS's popular pattern and graphics reports in one convenient place. ASSET GALLERY: FS team's editorial content, which includes mood images, bespoke videos, original art, CADs, and color palettes, is easy to browse through, save, and share. MY FS AREA: Subscribers can access all their saved multimedia content (reports, videos, images, palettes, individual color chips) and drag-and-drop pieces to curate visually compelling mood and concept boards. ABOUT FS For over 22 years, FS (Fashion Snoops) has been a leading force in trend forecasting. Our curious team of experts serves clients in over 50 countries from the worlds of fashion, accessories, home decor, beauty, wellness, and other consumer-facing industries. With a powerful-yet-intuitive digital platform and decades of industry insight, FS is known for collaborating closely with clients. From boutique brands to Fortune 500 companies, we are helping to chart their path to a thriving business. Find your creative futures at fashionsnoops.com Contact Details Fashion Snoops Ashleigh Ralfe +44 7824 393164 ashleigh@fashionsnoops.com Company Website http://fashionsnoops.com/

May 01, 2023 09:00 AM Eastern Daylight Time

Image

Looking To Invest In Artificial Intelligence? Consider Evogene And Its Five Subsidiaries

TalkMarkets on EVGN

Evogene ( EVGN ) oversees five subsidiaries: Biomica, agPlenus, Lavie Bio, Castera, and Canonic. Each company uses Evogene’s unique artificial intelligence (AI) platform to develop products for different human medical needs and the agricultural industries. Their CPB platform, which stands for computational predictive biology, provides efficient ways to map plant phenotypes and microbial genomes. Their subsidiaries employ this AI technology to improve plant genetics, commercial fertilizers, and human medicines. Evogene produces revenue via its subsidiaries in two ways. It brings in benchmark and licensing payments from companies, who use its products and research. The main function of each subsidiary is to conduct research within their specialties using the CPB platform. The company also makes revenues from at-the-market sales of some of its products, including medical cannabis and wheat seed stimulant. Evogene’s stock price has been on the long-term downtrend which mirrors the trend of current market conditions. Global economic destabilization, ongoing bank crises, and historical interest rate hikes have diligently wrecked ideal market conditions for all stocks. These conditions may get worse and promise to stick around for a while. Buy ratings must be considered under these volatile conditions. Evogene has managed to stay afloat and its financial performance has continued to improve throughout this bearish period. Revenues are increasing for the company and each of its subsidiaries have new developments in their pipelines. The company’s stock price is trading at or near its all-time low and is undervalued at the moment. The situation may present an opportunity for investment with an eye to long-term growth. Updates on Evogene’s subsidiaries Lavie Bio uses Evogene’s MicroBoost AI engine to innovate agricultural supplements, like growth stimulates and fertilizer. The company recently received a $10 million investment from ICL (ICL) under a SAFE agreement. The company will collaborate with ICL to develop new agricultural products, here fertilizer. ICL is a global manufacturer of products made with specialty minerals. Lavie Bio currently has a growth stimulant on the market called Thrivus. Their spring wheat seed treatment, a microbiome-based bio-inoculant, was released on the market in the US during 2022 and sold out initially. The product increases summer wheat yields by up to four bushels per acre. The company plans to expand sales of Thrivus to other countries, like Canada and Europe. Lavie Bio also has a bio-fungicide, up for approval by the US EPA, which fights fruit rot and powdery mildew. It hopes to bring the fungicide to market in 2024 with focus on treating grape harvests. Biomica uses Evogene’s MicroBoose AI to develop microbiome-based medical treatments. The company currently has three drug candidates, which are undergoing clinical research and trials. BMC-128 is being developed to treat solid tumors in humans. The drug candidate is currently being tested on cancer patients in a Phase 1 clinical trial for human safety. The company hopes to begin Phase 1b/2 in 2024. The company’s second drug candidate, BMC333, is a microbiome therapeutic for treating inflammatory bowel disease. The drug, consisting of a combination of four live bacteria strains, has been tested on animals and found to reduce inflammation and tissue damage along the GI tract. The company plans a phase 1 trial in 2024. Biomica’s third drug candidate, BMC426, is being considered for the treatment of irritable bowel syndrome. The company has completed discovery with its candidate and has moved into pre-clinical trials. Biomica recently received a $20 million investment round led by Shanghai Healthcare Capital. The deal received regulatory approval from China today and allows for future investment rounds. AgPlenus uses Evogene’s ChemPass AI technology to develop commercial herbicides, insecticides, and fungicides. The company is currently focused on developing an herbicide which is effective on herbicide resistant weeds in commercial crops. AgPlenus’s current candidate, APH1, is an herbicide for treating unwanted weeds in large commercial grow operations. The company is in a partnership with Corteva ( CTVA ) for developing new herbicides. AgPlenus discovers new herbicide candidates, while Corteva tests them and ultimately licensing them. AgPlenus has other products under development, including a fungicide. Casterra, Evogene’s newest subsidiary, uses the company’s GeneRaptor AI technology to innovate novel castor plant varieties. Castor seeds processed into oil are used worldwide for bio-diesel and are currently in high demand. The company recently signed an agreement with a European energy company to provide castor seeds and technical support for a set of cultivation sights in Africa. Casterra has another agreement with Titan Castor Farms in Zambia for production and distribution of its castor seeds. The company feels that castor seeds may be the next major catalyst for its financial performance and shareholders. Canonic uses Evogene’s GeneRaptor AI technology to map and breed cannabis genetics for medical applications. The cannabis strains are bred to have specific traits for treating certain medical conditions. The company has recently released its second-generation cannabis products in the Israeli medical cannabis market. These new genetics were perfected at Canonic’s cannabis research facility and boast a high THC potency of 24%. The products consist of a selection of dried flowers and THC oil tinctures. Evogene’s financial performance Over the last four quarters, revenues have increased for Evogene. In their Q3-2022 filings, the company reported revenues of $466K showing a more than 200% increase YoY. In their recent Q4-2022 filings, the company reported revenues of $660K more than 100% increase YoY and a 40% increase from last quarter. The company also reported its 2022 fiscal year performance. Revenue increased more than 80% from $930K (2021) to 1.675 million (2022). Evogene receives revenues through benchmark and licensing payments from companies usings its products and research. The company also has revenues from medical cannabis sales by Canonic and from sales of Lavio Bio’s wheat stimulant. The company expects future revenues from Casterra and its recent agreements to supply castor seed and support. The market consensus for Q1-2023 revenue estimates is $2 million, a significant increase from previous quarters. Whether or not the company hits that estimate, its revenues should continue to grow from quarter to quarter. Evogene reported a net loss of $3.8 million for Q4-2022, which is less than previous quarters. The company has a cash position of $31.860 million and receives enough money in receivables to continue its business and research strategy for some time. Evogene is set to receive $3.5 million from Bayer ( BAYRY ) for their seed trait collaboration agreement. The company’s largest operational cost is funding research and development. The company has no bank debt. The company requires about $4 million per quarter to operate. Evogene competes with such companies as Schödinger ( SDGR ), Ginkgo Networks ( DNA ), Exscientia ( EXAI ), and Relay Therapeutics ( RLAY ). Evogene is currently undervalued Evogene’s stock price has been trading under a $1 per share since September 2022. In January, the price began an uptrend towards a dollar per share, but in February a new down trend emerged. The price now sits near its all-time low around $.63 per share. There is a possibility that the company’s stock will have to undergo a reverse split to meet the minimum price requirements of $1 per share. So long as the stock price is low, the company remains undervalued. Its stock is currently trading at.49x NTM Total Enterprise Value / Revenue. The situation may present an opportunity to begin a long-term investment in the company’s stock. Evogene’s financials are sound and its research and product pipelines are robust. Greater market volatility may be the largest barrier in giving the company a strong buy rating for the time being. Conclusion Keep your eye on Evogene’s financial performance and research developments from its five subsidiaries. The company has been perfecting AI technology for a long time and its applications have produced innovative products. The company will continue to raise revenue numbers with its at the market products and benchmarks payments. Evogene has plenty of incoming receivables to fuel its research agenda and business strategy. The company’s stock is at an all-time low, while the company’s financial performance is on par with expectations. The metrics show that the company is currently undervalued and an investment opportunity may soon present itself. Larger market conditions will help decide if a long-term investment is tenable. Originally published at TalkMarkets. Related Articles: Biomica Announces Closing Of $20 Million Financing Round Led By Shanghai Healthcare Capital Evogene Offers An Excellent Risk/Reward Ratio More By This Author: Up In Smoke: Cannabis In A Bear Market Disclosure: This article is part of a new “UnderCovered” series of exclusive articles featuring companies with limited coverage. Authors are compensated by TalkMarkets for their time, and otherwise represent their own assessments and opinions. Authors are not compensated by the subject companies in any way. This article is also part of our IR Insights Initiative in which articles about participating companies can receive greater visibility. To learn more click here. Author Disclosure: No position in EVGN at the time of writing. Contact Details TalkMarkets ir@talkmarkets.com

April 28, 2023 09:00 AM Eastern Daylight Time